November 8, 2024
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024
September 24, 2024
Revelation Biosciences’ Gemini Induces Dose Dependent Significant Increases in IL-10
August 21, 2024
Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds
August 9, 2024
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024
June 24, 2024
Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini
June 13, 2024
Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini
May 10, 2024
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024
March 13, 2024
Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)
March 12, 2024
Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference
March 4, 2024
Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini
February 13, 2024
Revelation Biosciences Inc. Receives Invitation to give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)
February 5, 2024
Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering
February 1, 2024
Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering
January 30, 2024
Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)
January 23, 2024
Revelation Biosciences Inc. Announces 1-for-30 Reverse Stock Split Effective January 25, 2024
November 13, 2023
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2023
October 12, 2023
Gemini Induces Pharmacologic Activity and Related Physiologic Changes in Multiple Preclinical Studies
October 4, 2023
Revelation Biosciences, Inc. to Present at the 2023 ROTH Healthcare Opportunities Conference
October 2, 2023
Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of Directors
August 11, 2023
Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2023
June 29, 2023
REMINDER: Revelation Biosciences, Inc. Urges All Stockholders to Vote at the 2023 Annual Meeting of Stockholders
June 12, 2023
Revelation Biosciences Inc. Announces Adjournment of 2023 Annual Meeting of Stockholders to July 7, 2023 and Additional Proposal
May 22, 2023
Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2023 and Recent Corporate Progress
March 30, 2023
Revelation Biosciences Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Recent Corporate Progress
March 13, 2023
Revelation Biosciences Inc. Appoints Dr. Julia Bohannon and Dr. Antonio Hernandez to Scientific Advisory Board
March 6, 2023
Revelation Biosciences Inc. to Participate in a Fireside Chat at the 35th Annual Roth Conference
February 13, 2023
Revelation Biosciences Inc. Announces Closing of $15.6 Million Public Offering
February 9, 2023
Revelation Biosciences Inc. Announces Pricing of $15.6 Million Public Offering
February 7, 2023
Revelation Biosciences Inc. Announces Preclinical Biomarker Data Supporting Activity of REVTx-300
January 31, 2023
Revelation Biosciences Inc. Announces 1-for-35 Reverse Stock Split effective February 1, 2023 and Results of Special Meeting of Stockholders
January 10, 2023
Revelation Biosciences Inc. Announces Mandatory Unit Separation to Occur on January 13, 2023
November 18, 2022
Revelation Biosciences Inc. Announces Future Clinical Development Plans Based on Recent Biomarker Analysis and Significant Reduction in New Collagen Deposition (Fibrosis) in Preclinical Model
November 10, 2022
Revelation Biosciences Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2022 and Recent Corporate Progress
October 25, 2022
Revelation Biosciences Inc. Announces Positive Results in Preclinical Model of Acute and Chronic Kidney Disease
October 6, 2022
Revelation Biosciences Inc. and Vanderbilt University Enter Exclusive Worldwide License Agreement
August 15, 2022
Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Recent Corporate Progress
July 29, 2022
Revelation Biosciences Inc. Announces Closing of $5 Million Public Offering
July 26, 2022
Revelation Biosciences Inc. Announces Pricing of $5 Million Public Offering
July 22, 2022
Revelation Biosciences Inc. Announces Topline Data for Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis
July 14, 2022
Revelation Biosciences Inc. Completes Database Lock for its Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis
June 13, 2022
Revelation Biosciences Inc. Announces Completion of Dosing for a Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis
May 23, 2022
Revelation Biosciences Inc. Announces Safety Monitoring Committee Recommendation for Continuing Evaluation of REVTx-99b for the Treatment of Allergic Rhinitis
May 16, 2022
Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2022 and Recent Corporate Progress
April 6, 2022
Revelation Biosciences Inc. Announces Conference Call to Provide a Corporate Update
March 30, 2022
Revelation Biosciences Inc. Announces Primary Endpoint Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99a for the Prevention of H3N2 Influenza Infection
March 24, 2022
Revelation Biosciences Inc. Outlines Details on the Upcoming Data Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx 99a for the Prevention of H3N2 Influenza Infection
March 22, 2022
Revelation Biosciences Inc. to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC
March 15, 2022
Revelation Biosciences Inc. Announces Enrollment and Dosing Complete for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx‑99 for the Prevention of H3N2 Influenza Infection
March 8, 2022
Revelation Biosciences Inc. to Present at the 34th Annual Roth Conference
February 7, 2022
Revelation Biosciences Inc. to Present at 2022 BIO CEO & Investor Conference
January 24, 2022
Revelation Biosciences Raises $7.76 Million in Equity Financing
January 20, 2022
Revelation Biosciences Inc. Announces First Group of Patients Dosed in Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99 for the Prevention of H3N2 Influenza Infection
January 18, 2022
Revelation Biosciences Inc. Announces First Patient Enrolled and Dosed in Phase 1b Clinical Study of REVTx-99 for the Treatment of Allergic Rhinitis
January 11, 2022
Revelation Biosciences Inc. Announces Data Demonstrating REVTx-99 In Vitro Anti-Viral Activity Against SARS-CoV-2; Commencement of Trading as a Public Company
December 22, 2021
Petra Acquisition, Inc. Announces Share Redemption Backstop and Forward Purchase Agreements in Connection with Revelation Biosciences, Inc. Business Combination
December, 16, 2021
Petra Acquisition, Inc. Announces Special Meeting of Stockholders to Approve Business Combination with Revelation Biosciences, Inc.
December 6, 2021
Revelation Biosciences Inc. Appoints Joseph A. Bellanti, M.D. to Scientific Advisory Board
December 1, 2021
Revelation Biosciences Inc. Announces Initiation of a Phase 2b Study to Assess Efficacy of Intranasal REVTx-99 for The Prevention of H3N2 Influenza
November 29, 2021
Revelation Biosciences Inc. Announces Creation and Appointments to Scientific Advisory Board
November 15, 2021
Revelation Biosciences Inc. Announces Initiation of a Phase 1b Clinical Study of REVTx-99 for the Experimental Treatment of Allergic Rhinitis and Chronic Nasal Congestion
November 1, 2021
Revelation Biosciences Inc. Engages Partnering Advisor, MedWorld Advisors, to Optimize Value of the Company’s Diagnostic Tool, REVIDTM
October 25, 2021
Revelation Biosciences Inc. Engages Destum Partners Inc. to Identify a Strategic Partners for REVTx-99 (Ex-US) and REVTx-200 (Worldwide)
October 4, 2021
Revelation Biosciences Inc. Receives Approval to Begin a Phase 1b Clinical Study of REVTx-99 as an Experimental Treatment for Allergic Rhinitis and Chronic Nasal Congestion
September 28, 2021
Revelation Biosciences Inc. Receives Approval to Initiate Phase 2b Viral Challenge Study of REVTx-99, an Experimental Prophylactic Treatment for the Prevention of Respiratory Viral Infections
August 30, 2021
Revelation Biosciences, Inc., a Life Sciences Company Developing Therapeutics and Diagnostics for Respiratory Viral Infections, Including COVID-19, to Become Publicly Traded through a Merger with Petra Acquisition, Inc.
June 9, 2021
Revelation Biosciences Inc. to Present at 2021 BIO Digital Conference
May 5, 2021
Revelation Biosciences Inc. Announces Results of Phase 1 Clinical Study of REVTx 99, an Experimental Therapy for the Prevention of Respiratory Viral Infection
February 11, 2021
Revelation Biosciences Inc. to Present at BIO CEO & Investor Digital Conference
February 2, 2021
Revelation Biosciences Inc. Completes Dosing of Five Single Dose Cohorts and Receives Approval to Initiate a Multiple Dose Cohort to Phase 1 Clinical Study of REVTx 99, an Experimental Treatment for Respiratory Viral Infection, Including COVID 19
February 1, 2021
Revelation Biosciences Inc. Announces Closing of $4.4 Million in Series A-1 Financing
January 11, 2021
Curt LaBelle, M.D. Appointed to Revelation Biosciences, Inc. Board of Directors
January 5, 2021
Revelation Biosciences Inc. Announces $9.1 Million Common Stock and Series A Financing
November 16, 2020
Revelation Biosciences Inc. Announces the Start of a Phase 1 Clinical Study for REVTx 99, an Experimental Treatment for Respiratory Viral Infection, Including COVID 19
October 15, 2020
Revelation Biosciences Inc. Appoints Jess Roper to Board of Directors
October 7, 2020
Revelation Biosciences Inc. Receives TGA Acknowledgment to Start a Phase 1 Clinical Study of REVTx‑99 an Experimental Treatment for COVID‑19
October 1, 2020
Revelation Biosciences Inc. Receives Approval to Start a Phase 1 Clinical Study of REVTx‑99 an Experimental Treatment for COVID‑19
